Literature DB >> 22322605

The Role of preload and leakage correction in gadolinium-based cerebral blood volume estimation determined by comparison with MION as a criterion standard.

J L Boxerman1, D E Prah, E S Paulson, J T Machan, D Bedekar, K M Schmainda.   

Abstract

BACKGROUND AND
PURPOSE: Contrast extravasation in DSC-MRI potentiates inaccup
an class="Species">rat
e and imprecise estimates of glioma rCBV. We tested assertions that preload and postprocessing algorithms minimize this error by comparing Gd-rCBV using permutations of these 2 techniques with criterion standard rCBV using MION, an intravascular agent.
MATERIALS AND METHODS: We imaged 7 Fisher rats with 9L gliosarcomas, by using 3T gradient-echo DSC-MRI with MION (2.0 mg Fe/kg) and staged injection of Gd-diethylene triamine pentaacetic acid: a 0.1-mmol/kg bolus provided no preload (P-) data and served as preload (P+) for a subsequent 0.2-mmol/kg bolus. We computed MION-rCBV (steady-state ΔR2*, tumor versus normal brain) and Gd-rCBV ΔR2* [t] integration) without (C-) and with (C+) postprocessing correction, thereby testing 4 correction permutations: P-C-, P-C+, P+C-, and P+C+. We tested whether each permutation reduced bias and variance of the Gd/MION rCBV differences by using generalized estimating equations and Fmax statistics (P < .05 significant).
RESULTS: Gd-rCBV progressively better approximated MION-rCBV with increasing leakage correction. There was no statistically significant bias for the mean percentage deviation of Gd-rCBV from MION-rCBV for any correction permutation, but there was significantly reduced variance by using P+C- (22-fold), P-C+ (32-fold), and P+C+ (267-fold) compared with P-C-. P+C+ provided significant additional variance reduction compared with P+C- (12-fold) and P-C+ (8-fold). Linear regression of Gd-rCBV versus MION-rCBV revealed P+C+ to have the closest slope and intercept compared with the ideal, substantially better than P+C-.
CONCLUSIONS: Preload and postprocessing correction significantly reduced the variance of Gd-rCBV estimates, and bias reduction approached significance. Postprocessing correction provide significant benefit beyond preload alone.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22322605      PMCID: PMC4331024          DOI: 10.3174/ajnr.A2934

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  44 in total

1.  Perfusion MR imaging of brain neoplasms.

Authors:  J C Wong; J M Provenzale; J R Petrella
Journal:  AJR Am J Roentgenol       Date:  2000-04       Impact factor: 3.959

2.  Simultaneous quantitative cerebral perfusion and Gd-DTPA extravasation measurement with dual-echo dynamic susceptibility contrast MRI.

Authors:  E P Vonken; M J van Osch; C J Bakker; M A Viergever
Journal:  Magn Reson Med       Date:  2000-06       Impact factor: 4.668

3.  Blood volume of gliomas determined by double-echo dynamic perfusion-weighted MR imaging: a preliminary study.

Authors:  H Uematsu; M Maeda; N Sadato; T Matsuda; Y Ishimori; Y Koshimoto; H Kimura; H Yamada; Y Kawamura; Y Yonekura; H Itoh
Journal:  AJNR Am J Neuroradiol       Date:  2001 Nov-Dec       Impact factor: 3.825

Review 4.  Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging.

Authors:  Soonmee Cha; Edmond A Knopp; Glyn Johnson; Stephan G Wetzel; Andrew W Litt; David Zagzag
Journal:  Radiology       Date:  2002-04       Impact factor: 11.105

5.  Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study.

Authors:  Stephan G Wetzel; Soonmee Cha; Glyn Johnson; Peter Lee; Meng Law; David L Kasow; Sean D Pierce; Xiaonan Xue
Journal:  Radiology       Date:  2002-09       Impact factor: 11.105

6.  High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas.

Authors:  H J Aronen; F S Pardo; D N Kennedy; J W Belliveau; S D Packard; D W Hsu; F H Hochberg; A J Fischman; B R Rosen
Journal:  Clin Cancer Res       Date:  2000-06       Impact factor: 12.531

7.  T1- and T2*-dominant extravasation correction in DSC-MRI: part I--theoretical considerations and implications for assessment of tumor hemodynamic properties.

Authors:  Atle Bjornerud; A Gregory Sorensen; Kim Mouridsen; Kyrre E Emblem
Journal:  J Cereb Blood Flow Metab       Date:  2011-04-20       Impact factor: 6.200

8.  Utility of simultaneously acquired gradient-echo and spin-echo cerebral blood volume and morphology maps in brain tumor patients.

Authors:  K M Donahue; H G Krouwer; S D Rand; A P Pathak; C S Marszalkowski; S C Censky; R W Prost
Journal:  Magn Reson Med       Date:  2000-06       Impact factor: 4.668

9.  Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade.

Authors:  Meng Law; Stanley Yang; James S Babb; Edmond A Knopp; John G Golfinos; David Zagzag; Glyn Johnson
Journal:  AJNR Am J Neuroradiol       Date:  2004-05       Impact factor: 3.825

10.  Measuring blood volume and vascular transfer constant from dynamic, T(2)*-weighted contrast-enhanced MRI.

Authors:  Glyn Johnson; Stephan G Wetzel; Soonmee Cha; James Babb; Paul S Tofts
Journal:  Magn Reson Med       Date:  2004-05       Impact factor: 4.668

View more
  56 in total

1.  Cerebral blood volume mapping with ferumoxytol in dynamic susceptibility contrast perfusion MRI: Comparison to standard of care.

Authors:  Csanad G Varallyay; Eric Nesbit; Andrea Horvath; Peter Varallyay; Rongwei Fu; Seymur Gahramanov; Leslie L Muldoon; Xin Li; William D Rooney; Edward A Neuwelt
Journal:  J Magn Reson Imaging       Date:  2018-01-04       Impact factor: 4.813

2.  ASFNR recommendations for clinical performance of MR dynamic susceptibility contrast perfusion imaging of the brain.

Authors:  K Welker; J Boxerman; A Kalnin; T Kaufmann; M Shiroishi; M Wintermark
Journal:  AJNR Am J Neuroradiol       Date:  2015-04-23       Impact factor: 3.825

3.  A prognostic model based on preoperative MRI predicts overall survival in patients with diffuse gliomas.

Authors:  A Hilario; J M Sepulveda; A Perez-Nuñez; E Salvador; J M Millan; A Hernandez-Lain; V Rodriguez-Gonzalez; A Lagares; A Ramos
Journal:  AJNR Am J Neuroradiol       Date:  2014-01-23       Impact factor: 3.825

4.  Association of dynamic susceptibility contrast enhanced MR Perfusion parameters with prognosis in elderly patients with glioblastomas.

Authors:  Pejman Jabehdar Maralani; Elias R Melhem; Sumei Wang; Edward H Herskovits; Matthew R Voluck; Sang Joon Kim; Kim O Learned; Donald M O'Rourke; Suyash Mohan
Journal:  Eur Radiol       Date:  2015-02-14       Impact factor: 5.315

5.  Utility of Percentage Signal Recovery and Baseline Signal in DSC-MRI Optimized for Relative CBV Measurement for Differentiating Glioblastoma, Lymphoma, Metastasis, and Meningioma.

Authors:  M D Lee; G L Baird; L C Bell; C C Quarles; J L Boxerman
Journal:  AJNR Am J Neuroradiol       Date:  2019-08-01       Impact factor: 3.825

6.  Differentiation of Hemangioblastoma from Metastatic Brain Tumor using Dynamic Contrast-enhanced MR Imaging.

Authors:  J Cha; S T Kim; D-H Nam; D-S Kong; H-J Kim; Y K Kim; H Y Kim; G M Park; P Jeon; K H Kim; H S Byun
Journal:  Clin Neuroradiol       Date:  2016-03-07       Impact factor: 3.649

7.  Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics.

Authors:  Melissa A Prah; Mona M Al-Gizawiy; Wade M Mueller; Elizabeth J Cochran; Raymond G Hoffmann; Jennifer M Connelly; Kathleen M Schmainda
Journal:  J Neurooncol       Date:  2017-09-12       Impact factor: 4.130

8.  MRI Evaluation of Non-Necrotic T2-Hyperintense Foci in Pediatric Diffuse Intrinsic Pontine Glioma.

Authors:  O Clerk-Lamalice; W E Reddick; X Li; Y Li; A Edwards; J O Glass; Z Patay
Journal:  AJNR Am J Neuroradiol       Date:  2016-05-19       Impact factor: 3.825

9.  Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.

Authors:  Kathleen M Schmainda; Zheng Zhang; Melissa Prah; Bradley S Snyder; Mark R Gilbert; A Gregory Sorensen; Daniel P Barboriak; Jerrold L Boxerman
Journal:  Neuro Oncol       Date:  2015-02-02       Impact factor: 12.300

10.  Variability and accuracy of different software packages for dynamic susceptibility contrast magnetic resonance imaging for distinguishing glioblastoma progression from pseudoprogression.

Authors:  Zachary S Kelm; Panagiotis D Korfiatis; Ravi K Lingineni; John R Daniels; Jan C Buckner; Daniel H Lachance; Ian F Parney; Rickey E Carter; Bradley J Erickson
Journal:  J Med Imaging (Bellingham)       Date:  2015-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.